Literature DB >> 10469340

Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1.

G A Mashour1, H L Wang, R Cabal-Manzano, A Wellstein, R L Martuza, A Kurtz.   

Abstract

Neurofibromatosis type 1 is a common autosomal dominant disorder (incidence 1:3500) characterized by lesions that include neural crest derivatives such as Schwann cells and melanocytes. A critical event in the pathogenesis of neurofibromatosis type 1 is the heterozygous germ-line loss of the tumor suppressor gene NF1. Additional genetic and/or epigenetic events have been posited, including various alterations in growth factor expression. By in situ hybridization and immunohistochemistry, we demonstrate aberrant expression of the angiogenic and tumorigenic growth factor midkine in the skin of patients with neurofibromatosis type 1, but not normal individuals. We demonstrate that midkine expression is independent of the presence of neurofibromas, and thus appears to be associated with mutations in the NF1 gene. Furthermore, midkine-containing culture media is shown to stimulate the growth of human endothelial and neurofibroma-derived cells. In conclusion, we introduce the skin as a source of dysregulated growth factors in neurofibromatosis type 1, and suggest the further study of the angiogenic factor midkine in neurofibromatosis type 1 pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469340     DOI: 10.1046/j.1523-1747.1999.00699.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Increased serum concentrations of estrogen-induced growth factors Midkine and FGF2 in NF1 patients with plexiform neurofibroma.

Authors:  Isis Atallah; Ana M Cieza Rivera; Octavio M Rivero Lezcano; Laura Tascón-González; Carolina González-Cortés; Cristina Diez Tascón; Tania Fernández-Villa; Vicente Martín
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

2.  Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.

Authors:  Jianqiang Wu; Jason T Crimmins; Kelly R Monk; Jon P Williams; Maureen E Fitzgerald; Susan Tedesco; Nancy Ratner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 3.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 4.  Diagnosis and management of neurofibromatosis type 1.

Authors:  B R Korf
Journal:  Curr Neurol Neurosci Rep       Date:  2001-03       Impact factor: 6.030

5.  Midkine activation of CD8+ T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth.

Authors:  Xiaofan Guo; Yuan Pan; Min Xiong; Shilpa Sanapala; Corina Anastasaki; Olivia Cobb; Sonika Dahiya; David H Gutmann
Journal:  Nat Commun       Date:  2020-05-01       Impact factor: 14.919

6.  Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency.

Authors:  James A Walker; Jean Y Gouzi; Jennifer B Long; Sidong Huang; Robert C Maher; Hongjing Xia; Kheyal Khalil; Arjun Ray; David Van Vactor; René Bernards; André Bernards
Journal:  PLoS Genet       Date:  2013-11-21       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.